Alliancebernstein L.P. acquired a new position in Upstream Bio, Inc. (NASDAQ:UPB - Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor acquired 1,111,337 shares of the company's stock, valued at approximately $18,270,000. Alliancebernstein L.P. owned 2.07% of Upstream Bio as of its most recent SEC filing.
A number of other institutional investors and hedge funds have also recently bought and sold shares of UPB. Wellington Management Group LLP acquired a new position in shares of Upstream Bio during the 4th quarter valued at $25,632,000. Norges Bank bought a new stake in Upstream Bio in the fourth quarter worth about $16,440,000. JPMorgan Chase & Co. bought a new stake in Upstream Bio in the fourth quarter worth about $786,000. Corebridge Financial Inc. acquired a new stake in Upstream Bio in the 4th quarter valued at about $142,000. Finally, Charles Schwab Investment Management Inc. bought a new position in shares of Upstream Bio during the 4th quarter valued at about $2,225,000.
Upstream Bio Price Performance
Shares of NASDAQ UPB traded up $0.97 during midday trading on Friday, reaching $7.37. The company's stock had a trading volume of 303,708 shares, compared to its average volume of 327,123. Upstream Bio, Inc. has a one year low of $5.14 and a one year high of $29.46. The stock has a 50 day moving average price of $7.68.
About Upstream Bio
(
Free Report)
Upstream Bio, Inc, a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. It develops verekitug, a monoclonal antibody that targets and inhibits the thymic stromal lymphopoietin receptor. The company also develops therapies to treat severe asthma, chronic rhinosinusitis with nasal polyps, and chronic obstructive pulmonary disease.
Further Reading
Before you consider Upstream Bio, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Upstream Bio wasn't on the list.
While Upstream Bio currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
